• 1
    Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000; 124: 966978.
  • 2
    Bonadonna G, Valagussa P. Systemic therapy in resectable breast cancer. Hematol Oncol Clin North Am. 1989; 3: 727742.
  • 3
    Pritchard KI. Systemic adjuvant therapy for node-negative breast cancer: proven or premature? Ann Intern Med. 1989; 111: 14.
  • 4
    Harris J, Morrow M, Norton L. Malignant tumors of the breast. In: De VitaVT HellmanS, RosenbergSA, editors. Cancer: principles and practice of oncology. ( 5th edition) Philadelphia: Lippincott-Raven, 1997: 15911592.
  • 5
    American Society of Clinical Oncology. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol. 1996; 14: 28432877.
  • 6
    American Society of Clinical Oncology. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology. J Clin Oncol. 1998; 16: 793795.
  • 7
    Duigou F, Herlin P, Marnay J, Michels JJ. Variation of flow cytometric DNA measurement in 1,485 primary breast carcinomas according to guidelines for DNA histogram interpretation. Cytometry. 2000; 42: 3542.
  • 8
    Michels JJ, Duigou F, Marnay J. Flow cytometry in primary breast carcinomas. Prognostic impact of proliferative activity. Breast Cancer Res Treat. 2000; 62: 117126.
  • 9
    Hedley DW, Clark GM, Cornelisse CJ, Killander D, Kute T, Merkel D. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Report of the DNA Cytometry Consensus Conference. Cytometry. 1993; 14: 482485.
  • 10
    Shankey TV, Rabinovitch PS, Bagwell B, et al. Guidelines for implementation of clinical DNA cytometry. International Society for Analytical Cytology. Cytometry. 1993; 14: 472477.
  • 11
    Bloom HC, Richardson WW. Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957; 11: 359376.
  • 12
    Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer. 1989; 64: 19141921.
  • 13
    Bracko M, Us-Krasovec M, Cufer T, Lamovec J, Zidar A, Goehde W. Prognostic significance of DNA ploidy determined by high-resolution flow cytometry in breast carcinoma. Anal Quant Cytol Histol. 2001; 23: 5666.
  • 14
    Wingren S, Stal O, Sullivan S, Brisfors A, Nordenskjold B. S-phase fraction after gating on epithelial cells predicts recurrence in node-negative breast cancer. Int J Cancer. 1994; 59: 710.
  • 15
    Pinto AE, Andre S, Soares J. Short-term significance of DNA ploidy and cell proliferation in breast carcinoma: a multivariate analysis of prognostic markers in a series of 308 patients. J Clin Pathol. 1999; 52: 604611.
  • 16
    Baldetorp B, Ferno M, Fallenius A, et al. Image cytometric DNA analysis in human breast cancer analysis may add prognostic information in diploid cases with low S-phase fraction by flow cytometry. Cytometry. 1992; 13: 577585.
  • 17
    Balslev I, Christensen IJ, Rasmussen BB, et al. Flow cytometric DNA ploidy defines patients with poor prognosis in node-negative breast cancer. Int J Cancer. 1994; 56: 1625.
  • 18
    Bergers E, van Diest PJ, Baak JP. Cell cycle analysis of 932 flow cytometric DNA histograms of fresh frozen breast carcinoma material. Correlations between flow cytometric, clinical, and pathologic variables. MMMCP Collaborative Group. Multicenter Morphometric Mammary Carcinoma Project Collaborative Group Cancer. 1996; 77: 22582266.
  • 19
    Clark GM, Dressler LG, Owens MA, Pounds G, Oldaker T, McGuire WL. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med. 1989; 320: 627633.
  • 20
    Ewers SB, Attewell R, Baldetorp B, Borg A, Langstrom E, Killander D. Prognostic potential of flow cytometric S-phase and ploidy prospectively determined in primary breast carcinomas. Breast Cancer Res Treat. 1992; 20: 93108.
  • 21
    Ferno M, Baldetorp B, Borg A, Olsson H, Sigurdsson H, Killander D. Flow cytometric DNA index and S-phase fraction in breast cancer in relation to other prognostic variables and to clinical outcome. Acta Oncol. 1992; 31: 157165.
  • 22
    Lawry J, Rogers K, Duncan JL, Potter CW. The identification of informative parameters in the flow cytometric analysis of breast carcinoma. Eur J Cancer. 1993; 29A: 719723.
  • 23
    Sigurdsson H, Baldetorp B, Borg A, et al. Indicators of prognosis in node-negative breast cancer. N Engl J Med. 1990; 322: 10451053.
  • 24
    Silvestrini R, Daidone MG, Del Bino G,et al. Prognostic significance of proliferative activity and ploidy in node-negative breast cancers. Ann Oncol. 1993; 4: 213219.
  • 25
    Stal O, Wingren S, Carstensen J, et al. Prognostic value of DNA ploidy and S-phase fraction in relation to estrogen receptor content and clinicopathological variables in primary breast cancer. Eur J Cancer Clin Oncol. 1989; 25: 301309.
  • 26
    Stal O, Carstensen J, Hatschek T, Nordenskjold B. Significance of S-phase fraction and hormone receptor content in the management of young breast cancer patients. Br J Cancer. 1992; 66: 706711.
  • 27
    Wenger CR, Beardslee S, Owens MA, et al. DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat. 1993; 28: 920.
  • 28
    Spyratos F, Briffod M, Gentile A, Brunet M, Brault C, Desplaces A. Flow cytometric study of DNA distribution in cytopunctures of benign and malignant breast lesions. Anal Quant Cytol Histol. 1987; 9: 485494.
  • 29
    Meyer JS, Province MA. S-phase fraction and nuclear size in long term prognosis of patients with breast cancer. Cancer. 1994; 74: 22872299.
  • 30
    Stal O, Dufmats M, Hatschek T, et al. S-phase fraction is a prognostic factor in Stage I breast carcinoma. J Clin Oncol. 1993; 11: 17171722.
  • 31
    Chassevent A, Jourdan ML, Romain S, et al. S-phase fraction and DNA ploidy in 633 T1T2 breast cancers: a standardized flow cytometric study. Clin Cancer Res. 2001; 7: 909917.
  • 32
    Pinto AE, Andre S, Pereira T, Nobrega S, Soares J. Prognostic comparative study of S-phase fraction and Ki-67 index in breast carcinoma. J Clin Pathol. 2001; 54: 543549.
  • 33
    Klintenberg C, Stal O, Nordenskjold B, Wallgren A, Arvidsson S, Skoog L. Proliferative index, cytosol estrogen receptor and axillary node status as prognostic predictors in human mammary carcinoma. Breast Cancer Res Treat. 1986; 7 Suppl: S99S106.
  • 34
    Chassevent A, Geslin J, Bertrand G, et al. Place de l'analyse de DNA par cytométrie en flux dans l'évaluation du pronostic des cancers du sein [Place of flow cytometry DNA analysis in the prognosis of breast carcinoma]. Bull Cancer. 1990; 77( Suppl 1): 149S154S.
  • 35
    Clark GM, Wenger CR, Beardslee S, et al. How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer. Cancer. 1993; 71: 21572162.
  • 36
    Muss HB, Kute TE, Case LD, et al. The relation of flow cytometry to clinical and biologic characteristics in women with node negative primary breast cancer. Cancer. 1989; 64: 18941900.
  • 37
    Ottestad L, Pettersen EO, Nesland JM, Hannisdal E, Fossa SD, Tveit KM. Flow cytometric DNA analysis as prognostic factor in human breast carcinoma. Pathol Res Pract. 1993; 189: 405410.
  • 38
    Sigurdsson H, Baldetorp B, Borg A, et al. Flow cytometry in primary breast cancer: improving the prognostic value of the fraction of cells in the S-phase by optimal categorisation of cut-off levels. Br J Cancer. 1990; 62: 786790.
  • 39
    Wenger CR, Clark GM. S-phase fraction and breast cancer—a decade of experience. Breast Cancer Res Treat. 1998; 51: 255265.
  • 40
    Toikkanen S, Joensuu H, Klemi P. The prognostic significance of nuclear DNA content in invasive breast cancer—a study with long-term follow-up. Br J Cancer. 1989; 60: 693700.
  • 41
    Meyer JS, Friedman E, McCrate MM, Bauer WC. Prediction of early course of breast carcinoma by thymidine labeling. Cancer. 1983; 51: 18791886.
  • 42
    Rondez R, Yoshizaki C, Pirozynski W. Determination of nuclear DNA content and hormone receptors in breast cancer by the CAS 100 cell analysis system as related to morphologic grade and biochemical results. Anal Quant Cytol Histol. 1991; 13: 233245.
  • 43
    Hatschek T, Grontoft O, Fagerberg G, et al. Cytometric and histopathologic features of tumors detected in a randomized mammography screening program: correlation and relative prognostic influence. Breast Cancer Res Treat. 1990; 15: 149160.
  • 44
    Bosari S, Lee AK, Tahan SR, et al. DNA flow cytometric analysis and prognosis of axillary lymph node-negative breast carcinoma. Cancer. 1992; 70: 19431950.
  • 45
    McDivitt RW, Stone KR, Craig RB, Palmer JO, Meyer JS, Bauer WC. A proposed classification of breast cancer based on kinetic information: derived from a comparison of risk factors in 168 primary operable breast cancers. Cancer. 1986; 57: 269276.
  • 46
    Clayton F. Pathologic correlates of survival in 378 lymph node-negative infiltrating ductal breast carcinomas. Mitotic count is the best single predictor. Cancer. 1991; 68: 13091317.
  • 47
    Lynch J, Pattekar R, Barnes DM, et al. Mitotic counts provide additional prognostic information in Grade II mammary carcinoma. J Pathol. 2002; 196: 275279.
  • 48
    Jannink I, van Diest PJ, Baak JP. Comparison of the prognostic value of four methods to assess mitotic activity in 186 invasive breast cancer patients: classical and random mitotic activity assessments with correction for volume percentage of epithelium. Hum Pathol. 1995; 26: 10861092.
  • 49
    Gilchrist KW, Gray R, Driel-Kulker AM, et al. High DNA content and prognosis in lymph node positive breast cancer. A case control study by the University of Leiden and ECOG. ( Eastern Cooperative Oncology Group) Breast Cancer Res Treat. 1993; 28: 18.
  • 50
    Simpson JF, Gray R, Dressler LG, et al. Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. J Clin Oncol. 2000; 18: 20592069.
  • 51
    Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer. 2003; 97: 545553.
  • 52
    [No authors listed]. Adjuvant Therapy of Primary Breast Cancer 6th International Conference. Olma Messen St. Gallen. February 25-28, 1998 Abstracts. Eur J Cancer. 1998; 34 Suppl 1: S3S45.
  • 53
    Bergers E, Montironi R, van Diest PJ, Prete E, Baak JP. Interlaboratory reproducibility of semiautomated cell cycle analysis of flow cytometry DNA-histograms obtained from fresh material of 1,295 breast cancer cases. Hum Pathol. 1996; 27: 553560.
  • 54
    Michels JJ, Duigou F, Marnay J, et al. Flow cytometry and quantitative immunohistochemical study of cell cycle regulation proteins in invasive breast carcinoma. Cancer. 2003; 97: 13761386.